Vident Investment Advisory’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-22,246
Closed -$168K 948
2023
Q2
$168K Buy
22,246
+295
+1% +$2.39K 0.01% 1086
2023
Q1
$194K Buy
21,951
+2,655
+14% +$26.3K 0.01% 1111
2022
Q4
$176K Buy
19,296
+7,270
+60% +$63.4K 0.01% 1053
2022
Q3
$0 Buy
+12,026
New +$106K ﹤0.01% 1315
2016
Q2
Sell
-12,734
Closed -$682K 392
2016
Q1
$682K Buy
12,734
+9,121
+252% +$535K 0.04% 363
2015
Q4
$237K Buy
+3,613
New +$223K 0.03% 357

Other funds holding TEVA

Vident Investment Advisory's TEVA Position: Q3 2023 in Review

Vident Investment Advisory sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2023, closing a stake of 22,246 shares — an estimated $168K sold.

Vident Investment Advisory first reported a position in TEVA in Q4 2015 and held it in 6 quarters. The position peaked at $682K in Q1 2016. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Vident Investment Advisory reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 22,246 Teva Pharmaceutical Industries Limited shares in Q3 2023, an estimated $168K.
  • Vident Investment Advisory first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 6 quarters.
  • Vident Investment Advisory's Teva Pharmaceutical Industries Limited position peaked at $682K in Q1 2016.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.